The majority of gliomas (92%) which included test results of IDH mutation and 1p/19q codeletion status were categorized as astrocytomas, oligodendrogliomas, and GBM as defined by the 2016 CNS WHO classification [3]. This evidence concerns the gene IDH2 and astrocytoma (excluding glioblastoma).